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Objective. To estimate the annual incidence of systemic lupus erythematosus (SLE) over a 10-year period in the UK, and
to examine age-, sex-, and region-specific rates.
Methods. The study was based on the UK General Practice Research Database (GPRD), which covers 5% of the UK
population. We estimated SLE incidence rates, during the period 1990–1999, among persons registered with practices
contributing to the GPRD, representing >33 million person-years of observation.
Results. A total of 1,638 patients with incident SLE (1,374 females, 264 males) were identified. The age-standardized SLE
incidence in the UK during the 1990s was 7.89 per 100,000 (95% confidence interval [95% CI] 7.46, 8.31) for females and
1.53 per 100,000 (95% CI 1.34, 1.71) for males (overall female-to-male ratio 5.2:1). Peak incidence occurred at age 50–54
years for females and 70–74 years for males. There was a small but insignificant increase of SLE incidence over the 10
years among females but not males. No clear association between latitude and SLE incidence was found, but regional
variations existed, with age-standardized rates ranging from 3.56 per 100,000 (95% CI 3.00, 4.13) for the West Midlands
to 7.62 per 100,000 (95% CI 5.59, 9.65) for Northern Ireland.
Conclusion. This study provides updated estimates of SLE incidence in the UK. Standard methodology throughout the
study period and target population allowed for comparison of rates over time and across regions.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune
disorder with significant morbidity and mortality for
which there is a paucity of epidemiologic information.
Previous active surveillance studies of SLE incidence have
been confined to relatively small geographic areas (1–3),
and the most recent of these studies from the UK dates
back to 1991 (1). Due to the diagnostic complexity of SLE
and its relative rarity, active surveillance studies require
considerable time and expense. For example, an ongoing
Centers for Disease Control and Prevention–sponsored
SLE surveillance study in southeastern Michigan, which
covers a base population of 2.3 million people, is operating
on direct costs of over 1 million US dollars for 3 years
(McCune WJ: personal communication). In contrast, exist-
ing research databases afford the opportunity to perform
studies of rare diseases at low cost. The UK General Prac-
tice Research Database (GPRD) is a population-based da-
tabase covering a representative sample (5%) of the UK
population of 60 million people. Internationally, this is
the largest research database of anonymized longitudinal
medical records from primary care. The present study
utilized the GPRD to study the incidence of SLE in En-
gland, Scotland, Wales, and Northern Ireland over a 10-
year period (1990–1999) with detailed analysis of geo-
graphic variation and time trends.
PATIENTS AND METHODS
Database and study population. More than 98% of the
UK population is registered with a general practitioner
Dr. Somers’ work was supported by a United Kingdom
Overseas Research Student award, the Herb and Carol Am-
ster Lupus Research Fund, and an Arthritis Foundation
Doctoral Dissertation award. Dr. Smeeth’s work was sup-
ported by a United Kingdom Medical Research Council cli-
nician scientist fellowship. Ms Schoonen’s work was sup-
ported by a GlaxoSmithKline PhD Studentship.
Emily C. Somers, PhD, ScM (current address: University
of Michigan, Ann Arbor), Sara L. Thomas, MB BS, MSc,
PhD, Liam Smeeth, MBChB, MRCGP, MSc, PhD, W. Marieke
Schoonen, MSc, Andrew J. Hall, MB BS, MSc, PhD: London
School of Hygiene and Tropical Medicine, London, UK.
Dr. Hall is a nonexecutive director for and has received
consulting fees and/or honoraria (less than $10,000) from
the Health Protection Agency (UK).
Address correspondence to Emily C. Somers, PhD, ScM,
University of Michigan, Division of Rheumatology, 1500
East Medical Center Drive, 3918 Taubman Center, Ann Ar-
bor, MI 48109-0358. E-mail: emsomers@umich.edu.
Submitted for publication March 6, 2006; accepted in
revised form September 1, 2006.
Arthritis & Rheumatism (Arthritis Care & Research)
Vol. 57, No. 4, May 15, 2007, pp 612–618
DOI 10.1002/art.22683
© 2007, American College of Rheumatology
ORIGINAL ARTICLE
612
working in the National Health Service (NHS). The GPRD
covers 5% of NHS patients, and consists of anonymized
electronic clinical records of patients registered with con-
tributing general practices. At any given time, there are 3
million active patients in the GPRD. The practices in-
cluded in the GPRD are broadly representative of practices
in the UK in terms of geographic distribution, practice
sizes, and the age and sex distributions of registered pa-
tients (4). These practices are under contract to register all
active patients and to record all significant morbid events,
including all hospitalizations or specialist referrals and
outcomes, prescriptions, significant test results, and dates
of onset for chronic or recurrent conditions (4).
Contributing practices must meet a range of data quality
criteria before they are included in the GPRD, and ongoing
quality control is conducted for practices to remain up to
standard (5). The quality of the information in the data-
base, including the completeness of recording of diagnoses
made in medical facilities outside the practice, has been
validated in a number of independent studies and has
been found to be high (5). There is excellent agreement
between prescribing data from the GPRD and national data
from the UK Prescription Pricing Authority (6).
The period for this study was January 1, 1990 to Decem-
ber 31, 1999. Ethics approval for this research was ob-
tained from the Scientific and Ethical Advisory Group,
which reviews all GPRD proposals.
Identification of SLE cases. The Oxford Medical Infor-
mation Systems (OXMIS) (7) and Read (8) coding systems
are used to record clinical data in the GPRD. OXMIS and
Read codes for SLE were identified from a coding dictio-
nary by 4 investigators (3 physician epidemiologists and 1
rheumatic disease epidemiologist) and were verified by a
rheumatologist whose subspecialty is SLE (list of codes
available upon request). Patients with at least 1 SLE code
in their medical history were identified. The date corre-
sponding to the first SLE record represented the date of
diagnosis. With the exception of subacute cutaneous lupus
erythematosus (SCLE), codes for cutaneous variants of lu-
pus were not considered to represent SLE. SCLE was re-
tained because a high proportion of patients with SCLE
develop SLE.
SLE cases were considered to be potentially incident if
the date of diagnosis occurred during the study period and
while the patient was registered with a practice contribut-
ing data to the GPRD. Incidence rates have been shown to
be overestimated during the initial months after patients
first register with a contributing practice because prevalent
disease is recorded but may not be correctly dated as a past
diagnosis. The relevant period during which this overes-
timation occurs varies by disease (9). We used a modifica-
tion of the method described by Lewis et al (9) to deter-
mine the correct period. We considered all SLE cases with
a date of diagnosis occurring after the first day of followup
in the GPRD. Hazard function estimates were computed by
the classic life table method, using the first date within the
analysis time window (i.e., the later of the patient regis-
tration date or the date the practice started contributing
data) as the time origin and the time of the first SLE-related
medical code per patient as the event date. The analysis
was stratified according to whether patients registered
with a general practice before or after the practice began
contributing data to the GPRD. Evaluation of the hazard
function demonstrated that the hazard of diagnosis be-
came constant 12 months after patients had registered
with a contributing general practice, and was constant
from the beginning of followup for patients already regis-
tered with a practice when the practice started contribut-
ing data to the GPRD. Therefore, for our study, at least 12
months of followup after patient registration were neces-
sary before the patient was eligible to be an incident SLE
case.
Statistical analysis. Crude and stratum-specific inci-
dence rates were computed per 100,000 person-years.
Rates were estimated by dividing the number of incident
cases by the GPRD population denominator. Denominators
for the entire GPRD population were available by sex, age,
and NHS region (a geographic proxy) for each calendar
year at its midpoint (July 1). Age-standardized rates were
calculated using the direct method, with weights based on
the European Standard Population (10), and 95% confi-
dence intervals (95% CIs) for age-standardized rates were
calculated based on the Poisson approximation. Age-stan-
dardized annual incidence rates were calculated during
the 1990s to determine whether rates changed over the
study period. Linear regression was used to assess trends
over time. Standardized rate ratios and 95% CIs were used
for the comparison of age-standardized rates by region.
Data management and analysis were performed using SAS
software, version 8 (SAS Institute, Cary, NC) and Stata
software, version 8 (StataCorp, College Station, TX).
RESULTS
SLE cases. There were a total of 33,666,320 person-
years of observation in the GPRD over the study period of
1990–1999, and 2,116 potential patients with SLE were
identified as having diagnosis dates during this time. Of
these patients, 22 were excluded due to having exclusively
cutaneous lupus codes. A further 456 patients were prev-
alent (i.e., identified as having been diagnosed prior to
inclusion in the GPRD), leaving 1,638 incident SLE cases
for this analysis. A total of 1,374 (83.9%) patients with
incident SLE were female. The mean  SD age at diagnosis
for all patients was 47.3  16.4 years. On average, females
were diagnosed at an earlier age than males (mean  SD
age 46.3  16.3 versus 52.2  16.3 years; P  0.0001).
Incidence. Age and sex. Crude and age-standardized
incidence estimates for the decade of study are presented
in Table 1. The overall age-standardized incidence was
4.71 per 100,000 (95% CI 4.48, 4.94), 7.89 per 100,000
(95% CI 7.46, 8.31) for females and 1.53 per 100,000 (95%
CI 1.34, 1.71) for males. Age-specific rates for each sex are
displayed in Figure 1. Rates were similar for ages 0–14
years, but started to diverge sharply thereafter, with fe-
males having significantly higher rates of SLE incidence
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until approximately age 70. The peak incidence among
females occurred in the 50–54 year age group (13.38 per
100,000; 95% CI 11.13, 15.63), whereas males experienced
the highest incidence in the 70–74 year age group (4.36 per
100,000; 95% CI 2.71, 6.00).
Temporality. Sex-specific and overall incidence rates
by year are depicted in Figure 2. Among males, the inci-
dence appeared stable over the entire decade. Based on
linear regression, there appeared to be a modest trend of
increasing incidence among females, equivalent to an ad-
ditional 1 case per 100,000 females over the 10 years (95%
CI 0.1, 2.2), but this did not reach significance (P 
0.073).
Geography. Regions were classified according to the 8
NHS administrative regions in England and by country for
Wales, Northern Ireland, and Scotland (11). Age-standard-
ized incidence rates are displayed by region of the UK in
Figure 3. There was lack of a clear association between
SLE incidence and latitude (P  0.135). However, regional
variations of SLE incidence are noted. Age-standardized
rates ranged from a low of 3.56 per 100,000 (95% CI 3.00,
4.13) for the West Midlands to a high of 7.62 per 100,000
(95% CI 5.59, 9.65) for Northern Ireland. Standardized rate
ratios, comparing the age-standardized incidence for each
region with that overall for the UK, are displayed in Table
2. The West Midlands and South West of England had
significantly lower rates than the overall UK, whereas the
North West and Northern Ireland had significantly higher
incidence.
Treatment. Prescription drug data were collated for the
study population. The proportions of patients treated with
certain drugs are reported in Table 3. We looked at drugs
separately and also formed 2 composite categories. The
first was antimalarials and immunosuppressive agents,
which included the following drugs traditionally used for
Figure 1. Age- and sex-specific systemic lupus erythematosus
(SLE) incidence rates (per 100,000) with 95% confidence inter-
vals.
Figure 2. Overall and sex-specific age-standardized systemic lu-
pus erythematosus (SLE) incidence rates (per 100,000) with 95%
confidence intervals, by calendar year. The linear best fit lines are
also displayed.
Figure 3. Age-standardized systemic lupus erythematosus inci-
dence rates (per 100,000) by region.
Table 1. Crude and age-standardized systemic lupus







Overall 1,638 4.87 4.71 4.48, 4.94
Female 1,374 8.01 7.89 7.46, 8.31
Male 264 1.60 1.53 1.34, 1.71
* 95% CI  95% confidence interval.
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the treatment of SLE or other rheumatic diseases: antima-
larials (hydroxychloroquine, chloroquine, or quinacrine),
azathioprine, cyclophosphamide, chlorambucil, cyclo-
sporin, methotrexate, and leflunomide. The other category
was rheumatoid arthritis (RA) disease-modifying antirheu-
matic drugs, which included 3 drugs used in rheumatol-
ogy almost exclusively for the treatment of RA: penicilla-
mine, gold, and sulfasalazine. This second category was
used to indicate the degree of potential overlap or misclas-
sification between patients with SLE and those with RA.
DISCUSSION
This large, population-based study included 1,638 pa-
tients with incident SLE and 33 million person-years of
observation over a 10-year period. The overall age-stan-
dardized SLE incidence estimate for the UK was 4.71 (95%
CI 4.48, 4.94). Sex-specific estimates were 7.89 per 100,000
(95% CI 7.46, 8.31) for females and 1.53 per 100,000 (95%
CI 1.34, 1.71) for males. Unfortunately, data on race, eth-
nicity, and birth location are not available in the GPRD,
although racial and ethnic differences in SLE incidence
have been well described (1,12). However, the size of this
study and uniformity of methodology throughout the
study period and catchment area enable more precise char-
acterization of sex- and age-specific incidence rates than
previously available, as well as exploration of temporal
and geographic trends.
The GPRD is well suited to the performance of disease
incidence studies because it provides a representative
sample of the UK population, and because general practi-
tioners in the UK serve as the gatekeepers for clinical care
for 98% of the population. The database systematically
includes diagnostic codes, but not all signs, symptoms, or
laboratory findings leading to a diagnosis, so there were
insufficient data to determine whether all cases fulfilled
the American College of Rheumatology (ACR) criteria
(13,14). However, when patients are referred for specialty
or tertiary care, the general practitioner electronically en-
ters salient findings from the consultant visits into the
GPRD. Therefore, even though the database is based in
general practice, the diagnosis of SLE was typically estab-
lished by a rheumatologist. Given access to universal
health coverage in the UK, and given that only a very small
segment of the population remains unregistered with the
NHS, the GPRD is an efficient means for capturing a cross-
section of patients with SLE covering the spectrum of
disease severity, not just those requiring the most aggres-
sive disease management. The major limitation of second-
ary data analysis studies, such as those based on the GPRD,
is that detailed data relevant to the disease of interest may
not be uniformly available (e.g., autoantibody profiles). In
contrast, active surveillance studies must expend a great
deal of resources identifying patients who have not
reached tertiary care centers. However, many active sur-
veillance studies have the advantage of being customized
for disease-specific investigations, which enables a more
thorough characterization of the study population.
Our SLE incidence data correspond to other published
estimates, although they are not directly comparable be-
cause we were unable to utilize the ACR criteria as our
case definition. However, the confidence intervals from
the current study are tighter given the large sample size. As
reviewed by Hochberg, international SLE incidence esti-
mates have been reported (during the last half of the 1900s)
to range from 1.8 to 7.6 per 100,000 (12). A systematic
review published in 1997 reported a weighted mean SLE
incidence, based on 10 studies, of 7.3 per 100,000 (15).
Two SLE surveillance studies from the UK were pub-
lished in the 1990s. Johnson et al performed an active
surveillance study based on the Metropolitan Districts of
Birmingham and Solihull, England (1). They identified 33
new cases of SLE and estimated incidence among adults
(ages 18 years) during calendar year 1991 to be 3.8 per
100,000 (95% CI 2.5, 5.1); sex-specific estimates were 6.8
per 100,000 (95% CI 4.4, 9.2) for females and 0.5 per
100,000 (95% CI 0.1, 1.7) for males. In the other UK study,
Hopkinson et al calculated the SLE incidence for the
Greater Nottingham metropolitan community for the pe-
Table 2. Standardized rate ratios and 95% confidence
intervals (95% CIs) comparing region-specific age-
standardized incidence rates with the overall systemic
lupus erythematosus incidence for the UK
Region
Standardized
rate ratio 95% CI
West Midlands 0.76 0.65, 0.88
South West 0.81 0.69, 0.94
Northern and Yorkshire 0.86 0.72, 1.02
Trent 0.93 0.79, 1.1
London 0.98 0.83, 1.15
Eastern 1.01 0.88, 1.17
Wales 1.02 0.81, 1.28
South East 1.07 0.92, 1.26
Scotland 1.12 0.87, 1.45
North West 1.35 1.17, 1.55
Northern Ireland 1.62 1.16, 2.27
Table 3. Prescription drugs used by systemic lupus




Antimalarials/immunosuppressive agents 793 (48.4)
Antimalarials 628 (38.3)
Azathioprine 226 (13.8)










* Values are the number (percentage). NSAID  nonsteroidal anti-
inflammatory drug; DMARDs  disease-modifying antirheumatic
drugs; RA  rheumatoid arthritis.
† Percentages do not equal 100% because individuals could have
had 1 drug.
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riod of January 1989 through April 1990 (2). Based on 23
incident cases, the age-standardized annual incidence es-
timates (adjusted to the European Standard Population,
which we also used) were 4.0 per 100,000 (95% CI 2.3, 5.6)
overall, 6.5 per 100,000 (95% CI 3.5, 9.4) for females, and
1.5 per 100,000 (95% CI 0.02, 2.9) for males. Both of these
studies used the ACR classification scheme (4 ACR cri-
teria) for their case definitions (13). Our regional estimates
are remarkably similar to the Birmingham and Nottingham
estimates cited above. We calculated the age-adjusted in-
cidence of SLE in the West Midlands (which encompasses
Birmingham) to be 3.56 per 100,000 (95% CI 3.00, 4.13)
and in Trent (which encompasses Nottingham) to be 4.37
per 100,000 (95% CI 3.65, 5.10).
The close comparability of our results with those of the
active surveillance studies described above serves as ex-
ternal validation for our methodology and as evidence that
the GPRD can be utilized for the study of SLE. Another
recent study endeavored to estimate SLE incidence during
the mid-1990s using the GPRD (16). However, this study
used a highly exclusive requirement that patients have at
least 3 years of available data to be eligible for the study
population. This requirement potentially led to a biased
estimate of SLE incidence: the overall estimated crude
incidence of SLE in this previous study was 3.02 per
100,000 compared with 4.87 per 100,000 in our study. As
Lewis et al (9) demonstrated, it is important to use a
disease-specific empirical approach for the delineation of
the time intervals used to distinguish prevalent from inci-
dent cases in the GPRD. We conducted such an analysis,
modifying the approach of Lewis et al (9) (as described in
the methods section). We therefore believe it is unlikely
that existing cases of SLE were misclassified as new cases
for the purposes of our study. Furthermore, the scope of
the prior GPRD-based SLE incidence study was limited in
that it did not include age-standardization, narrow age
categories, or data on annual or region-specific rates.
We were able to classify age in 5-year bands, whereas
many other studies are confined to using broader age cat-
egories due to smaller sample sizes. We found that peak
incidence of SLE occurred in the 50–54 year age category
for females and the 70–74 year category for males. Al-
though SLE is often considered to be a disease affecting
women in their reproductive years, other groups have
likewise reported peak incidence among women to occur
around or after menopause. Hopkinson et al reported a
peak incidence of 18.4 per 100,000 women in the 50–59
year age group in the Nottingham population (2), and
Jonsson et al reported a peak incidence of 12.5 per
100,000 women ages 55–64 years in a southern Sweden
population (17). We also included pediatric patients,
whereas some other studies have been restricted to adult
populations. Corresponding to the concept that autoim-
mune diseases tend to occur at a higher rate among females
beginning around puberty, we documented that the sex-
specific incidence rates became divergent with the 15–19
year age group, and that the ratio of female to male inci-
dence started to equalize again around age 70–74 years.
Annual incidence rates from 1990 to 1999 were exam-
ined to discern whether there was a temporal trend. There
was a small but insignificant increase of SLE incidence
over the 10 years among females, but not males. Based on
the linear trend among females in our study, the increase
we observed equates to 1 additional new case of SLE per
100,000 females over 10 years. Few studies have previ-
ously examined SLE incidence over time. Uramoto et al
described a roughly 3.5-fold increase in SLE incidence in
Rochester, Minnesota from 1950–1979 (1.51 per 100,000)
to 1980–1992 (5.56 per 100,000) (18). The magnitude of
increase was similar in both sexes, although slightly
higher among females. The authors stated that improved
recognition of mild disease over the 4 decades may have
contributed to the observed increase in incidence. Unfor-
tunately, an annualized rate of increase cannot be directly
calculated based on their data. However, the level of in-
crease that we detected among females appears to be sub-
stantially lower (approximately a 1.5-fold increase if ex-
trapolating our data over 40 years). In a study based in
Allegheny County, Pennsylvania from January 1985
through December 1990, McCarty et al reported stable
incidence of disease over the 6-year period (average 2.4 per
100,000) (3). Considering these studies together, it appears
that earlier indications of the increase in SLE incidence
may have been partially an artifact of changing diagnostic
capabilities, and that in more recent years data do not
support substantial changes in SLE incidence.
If SLE incidence is indeed relatively stable, it would
indicate that there have not been appreciable changes in
exposure to potential etiologic agents over time. However,
the slight suggestion that SLE incidence may be increasing
at a higher rate among females versus males raises the
question of whether there are risk factors for SLE with
differential patterns of exposure between the sexes. It will
be extremely useful to replicate incidence studies, using
the same methodologies and population bases originally
used, to determine how incidence measurements in the
future compare with those that can be extrapolated from
current data. Large databases, such as the GPRD, should be
utilized to the extent possible, because a high level of
statistical precision is necessary to detect small changes in
rates.
Although temporal trends were not striking, geographic
variations in SLE incidence were evident in our study. The
region with the lowest age-standardized rate was the West
Midlands (3.56 per 100,000; 95% CI 3.00, 4.13), and that
with the highest was Northern Ireland (7.62 per 100,000;
95% CI 5.59, 9.65). Although SLE incidence has not been
previously reported specifically for Northern Ireland,
prevalence was estimated in 1993 to be 25.4 per 100,000
(95% CI 22.1, 28.7), which does not appear to be unusually
high (19). It is unclear what factors may be involved with
such geographic variation within the UK. Latitude gradi-
ents have been observed based on ecologic studies of other
autoimmune diseases, such as multiple sclerosis (20,21)
and RA (22), with increasing latitude being associated
with higher rates of disease. We did not find a clear asso-
ciation between latitude and SLE incidence.
The biggest limitation of our study was the inability to
apply ACR criteria to all cases for SLE classification, or to
validate cases individually by performing detailed medi-
cal chart reviews. The ACR classification criteria would
allow for more direct comparison with other studies that
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have used the criteria, but their sensitivity was only 83%
in an external population when compared with the gold
standard of rheumatologist diagnosis (13). Therefore, it
can be argued that our study fills an important gap in the
data because it includes the subset of patients with SLE
that would have been false negatives according to the ACR
criteria. Nonetheless, it would have been preferable to also
directly compare incidence estimates based on the ACR
criteria had such data been uniformly available. Another
limitation was the lack of data regarding laboratory results
in the GPRD. Only 19 of the patients included in this study
had mention of antinuclear antibody (ANA) or anti-DNA
antibody positivity in their electronic records, which
clearly precludes the ability to use autoantibody data in
any fashion.
There were also limitations in using prescription drug
data to assist in the validation of SLE diagnoses. Because
drug exposure patterns vary considerably between pa-
tients with SLE, the lack of use of certain drugs cannot
exclude the possibility that a person has SLE. Conversely,
the use of certain antimalarials and immunosuppressive
agents can be highly suggestive of a rheumatic disease
diagnosis, but this information on its own cannot confirm
an SLE diagnosis. The diagnosis and initial management of
SLE occurs almost entirely in a hospital setting in the UK.
However, even when drug treatments are initiated by a
hospital consultant, continued long-term prescribing will
be undertaken by the general practitioner and will there-
fore be recorded in the GPRD record. However, a small
proportion of drugs will continue to be predominantly
prescribed by hospital consultants, in particular immuno-
suppressive agents such as cyclophosphamide. Thus the
GPRD record may not include all prescriptions related to a
patient’s SLE diagnosis.
Despite these issues, we attempted to estimate the extent
of potential overlap between RA and SLE. Of the 1,638
patients with SLE, 203 (12.4%) also had a code for RA at
some point in their medical record. Of these, 164 (80.8%)
had the RA code prior to their SLE diagnosis. RA accom-
panied by ANA positivity or extraarticular involvement
may infrequently be difficult to distinguish from SLE, al-
though actual RA overlap (“rhupus”) probably occurs in
no more than 1.5% of patients with SLE (23,24) as cited by
Wallace (25). It has also been observed that patients ini-
tially presenting with RA may evolve into having SLE after
the initial prodrome. For the patients in our series who
had an RA code prior to SLE diagnosis, it is possible that
early features of their disease were mistaken for RA, but it
is impossible to know how many patients with an RA code
after their SLE diagnosis may have had RA but were ini-
tially misclassified as having SLE. Misclassification of RA
as SLE is less likely than the converse because additional
clinical features are required.
In summary, this study provides updated estimates for
SLE incidence in the UK, with a high level of statistical
precision and detailed investigation of time trends and
geographic variation. To our knowledge, this surveillance
study includes the largest number of incident SLE cases to
date, particularly with regard to male patients with lupus.
Population-based databases such as the GPRD are under-
utilized for the study of rheumatic diseases, and serve as
important resources for cost-effective research that does
not include referral biases inherent in tertiary care set-
tings.
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